FMP
2seventy bio, Inc.
TSVT
NASDAQ
2seventy bio, Inc., a cell and gene therapy company, focuses on the research, development, and commercialization of treatments for cancer in the United States. Its products pipeline includes idecabtagene vicleucel; ide-cel or Abecma and bb21217; and CAR-T cell product candidates for the treatment of multiple myeloma. 2seventy bio, Inc. has a collaboration arrangement with Bristol-Myers Squibb Company. The company was incorporated in 2021 and is headquartered in Cambridge, Massachusetts.
4.99 USD
-0.005 (-0.1%)
TSVT Financial Statements
Year
2024
2023
2022
2021
Current Assets
187.26M
237.76M
300.88M
291.56M
Cash & Short Term Investments
174.75M
216.99M
266.27M
362.18M
Cash And Cash Equivalents
71.24M
74.96M
71.03M
130.41M
Short Term Investments
103.51M
142.03M
195.24M
134.64M
Net Receivables
0
13.41M
20.96M
17M
Inventory
0
0
13.64M
-114.12M
Other Current Assets
12.5M
0
0
0
Non-Current Assets
292.25M
327.66M
355.78M
468.11M
Property, Plant & Equipment
238.15M
278.11M
296.62M
310.45M
Goodwill And Intangible Assets
5.88M
6.59M
19.36M
21.95M
Goodwill
0
0
12.06M
12.06M
Intangible Assets
5.88M
6.59M
7.3M
9.89M
Long Term Investments
39.35M
4.82M
1.41M
97.12M
Tax Assets
0
0
0
0
Other Non-Current Assets
8.87M
38.14M
38.39M
38.59M
Other Assets
0
0
0
0
Total Assets
479.51M
565.43M
656.66M
759.67M
-
-
-
-
Current Liabilities
40.09M
59.78M
79.79M
98.39M
Accounts Payable
1.05M
6.03M
7.21M
6.02M
Short Term Debt
16.36M
13.78M
11.16M
9.77M
Tax Payables
0
0
0
0
Deferred Revenue
0
15.4M
3M
5M
Other Current Liabilities
22.67M
21.05M
32.41M
45.87M
Total Current Liabilities
40.09M
59.78M
79.79M
98.39M
Total Non-Current Liabilities
228.61M
250.35M
266.4M
301.46M
Long-Term Debt
227.35M
0
0
272.45M
Deferred Revenue
0
3.92M
5M
25.76M
Deferred Taxes Liabilities
0
0
0
0
Other Non Current liabilities
1.26M
2.42M
2.4M
-269.19M
Total Liabilities
268.7M
310.13M
346.2M
399.85M
Other Liabilities
0
0
0
0
Stockholders Equity
210.81M
255.3M
310.47M
359.82M
Common Stock
5k
5k
4k
2k
Retained Earnings
-568.46M
-511.22M
-293.65M
-39.49M
Accumulated Other Comprehensive Income/Loss
89k
-204k
-2.88M
-712k
Other Shareholders Equity
779.18M
0
0
0
Total Liabilities and Stockholders Equity
479.51M
565.43M
656.66M
759.67M
Retained Earning Schedule
Year
2024
2023
2022
2021
Retained Earnings (Previous Year)
-511.22M
-293.65M
-39.49M
0
Net Income
-57.25M
-217.57M
-254.14M
-276.21M
Stock Repurchases
0
0
0
0
Dividend Paid
0
0
0
0
Retained Earnings
-568.46M
-511.22M
-293.65M
-39.49M
Other Distributions
-57.25M
-217.57M
-254.15M
-39.49M
PPE Schedule
Year
2024
2023
2022
2021
Gross PPE
238.15M
278.11M
296.62M
310.45M
Annual Depreciation
7.1M
10.29M
11.53M
16.4M
Capital Expenditure
-707k
-13.87M
-22.84M
-19.57M
Net PPE
231.76M
281.69M
307.93M
313.62M
Intangible and Goodwill Schedule
Year
2024
2023
2022
2021
Acquisitions and Adjustments
0
-12.06M
0
-1.07M
Goodwill (Previous Year)
0
12.06M
12.06M
13.13M
Goodwill
0
0
12.06M
12.06M
All figures are in USD.
